Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
 
  • Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company; Completes $12M Equity Financing

    May 19th, 2009 No comments

    Agreement Focuses on Oral Ghrelin Antagonist Program, Targeting Type 2 Diabetes

    CAMBRIDGE, Mass. Elixir Pharmaceuticals, Inc., announced today the Company has entered into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Elixir following the successful completion of a Phase 2a clinical study of Elixir’s lead oral ghrelin antagonist, currently in preclinical, IND-enabling studies. Including the initial acquisition payment plus potential additional regulatory and sales milestone payments, the deal with Novartis could exceed $500 million. The agreement also includes a right to an exclusive worldwide license under pre-agreed conditions.

    “Type 2 diabetes continues to grow as one of the leading causes of excess morbidity and mortality around the world. New therapeutic options for this serious and chronic disease are sorely needed,” commented Paul Martha, M.D., Elixir’s President and CEO. “Elixir is a leader in the development of ghrelin antagonists for the treatment of type 2 diabetes and other major metabolic diseases. Therefore, we are extremely pleased to have reached agreement with Novartis on the tremendous potential value of our ghrelin antagonism program.”

    Elixir also announced it has completed a $12 million equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P. In addition to MPM, the financing round includes existing investors ARCH Venture Partners, Oxford Bioscience Partners, the Omega Fund and Physic Ventures. Concurrent with the investment, Dr. Kenneth Greenberg, a Principal at MPM Capital, has joined Elixir’s Board of Directors.

    “This major commitment by the MPM Bio IV NVS Strategic Fund L.P. reflects our belief in the potential of Elixir’s program to address important unmet needs in type 2 diabetes,” said Todd Foley, Managing Director at MPM Capital. “We are pleased to be a part of this successful financing, and we look forward to working closely with Elixir.”

    About Type 2 Diabetes

    Type 2 diabetes is a chronic metabolic disorder characterized by high blood sugar caused by defective insulin secretion, resistance to insulin action or a combination of both. It is a serious and debilitating disease, affecting more than 23 million Americans in the U.S. alone, 25% of whom are estimated to be undiagnosed. While there has been significant progress in the treatment of type 2 diabetes in the last decade, there is still an enormous unmet medical need worldwide.

    About Elixir’s Ghrelin Antagonist Development Program

    Ghrelin is a naturally occurring hormone secreted by the stomach, that acts primarily at the level of the hypothalamus in the brain. A key metabolic regulator, ghrelin plays a significant role in the regulation of glucose homeostasis, lipid profiles and body composition. It has been shown to stimulate appetite and food consumption, as well as play a central role in metabolism and energy storage. Elixir scientists have shown that genetically eliminating or “knocking out” the ghrelin receptor results in increased insulin sensitivity, improved triglyceride and cholesterol levels, and overall resistance to obesity in mice fed a high-fat diet.

    Using structure-assisted drug design, a method of creating chemical compounds based on an understanding of the configuration of the human ghrelin receptor, Elixir has internally discovered and developed a series of potent, small molecule antagonist compounds that block the ghrelin receptor. Oral administration of these compounds in animal models of diet-induced obesity and early diabetes resulted in similarly favorable metabolic effects to those seen in knockout models with respect to improved blood glucose levels, insulin resistance, HbA1c, triglycerides, total cholesterol, liver fat, body weight and white fat when compared to placebo. Elixir is completing preclinical studies of a clinical candidate prior to filing an investigational new drug (IND) application with the U.S. Food and Drug Administration.

    About Elixir Pharmaceuticals

    Elixir is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company’s scientific founders determined that modulation of specific genes can slow the aging process and increase longevity. Elixir is developing small molecule drugs that mimic these longevity responses, and these drugs will be used to treat a range of age-related diseases, including the major metabolic diseases.

    In addition to its oral ghrelin antagonist program, Elixir has two product candidates (Metgluna™ and Glinsuna™) which have recently completed Phase 3 clinical trials for the treatment of type 2 diabetes. The Company is also developing EX-1314, an oral drug for the treatment of GI hypomotility disorders including type 1 diabetic gastroparesis. Further, the Company’s SIRT product development program is exemplary of how Elixir continues to use its understanding of the pathways which slow the aging process to identify interesting targets for the development of drugs to treat metabolic disease.

    About MPM Capital

    MPM Capital is one of the world’s largest life science-dedicated venture investors. With committed capital under management in excess of $2.4 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation

    Source: Elixir Pharmaceuticals, Inc.

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 266,932 bad guys.

 

Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round


Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.


Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects


Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding


Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies


Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains


Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster


Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


 

By using this website you agree with our cookie policy